{"id":26,"date":"2026-07-14T18:10:15","date_gmt":"2026-07-14T18:10:15","guid":{"rendered":"https:\/\/blitzlab.eu\/blog-ipamorelin-cjc1295-kaufen\/"},"modified":"2026-10-23T23:36:58","modified_gmt":"2026-10-23T21:36:58","slug":"buy-ipamorelin-cjc-1295","status":"publish","type":"page","link":"https:\/\/blitzlab.eu\/en\/blog-ipamorelin-cjc1295-kaufen\/","title":{"rendered":"Ipamorelin + CJC-1295 kaufen \u2013 Forschungsleitfaden"},"content":{"rendered":"
\n
Home<\/a>\u203a<\/span>Blog<\/a>\u203a<\/span>Buy Ipamorelin + CJC-1295 (No DAC) 2026<\/span><\/div>\n\n

Buy Ipamorelin + CJC-1295 (No DAC) 2026 \u2014 GHRP\/GHRH Blend for GH Secretagogue Receptor Research (EU)<\/h1>\n

Peptide Research \u00b7 28 June 2026 \u00b7 12 min read \u00b7 Research Use Only<\/p>\n\n

\n In short:<\/strong> Ipamorelin + CJC-1295 (No DAC) is a Two-component blend<\/strong> of Ipamorelin (a GHRP-class pentapeptide) and CJC-1295 No DAC \/ Mod GRF 1-29 (a GHRH analogue-class 29-amino acid peptide). This research guide summarises, the published in vitro literature<\/strong> documented for both components \u2013 from peptide classification to GHS-R and GHRH receptor binding models. At BlitzLab as 5 mg + 5 mg Vial<\/strong> with batch-related Certificate of Analysis (COA)<\/a>, HPLC \u2265 99 %, EU delivery. Price: <\/strong>. For research use only (RUO).\n <\/div>\n
<\/svg> Scientific-factual research guide. Summarises published study observations. No health, dosage or application advice, no statement about suitability in humans. Research Use Only.<\/div>\n\n

Ipamorelin + CJC-1295 (No DAC) at a glance<\/h2>\n \n
Designation<\/th>Ipamorelin + CJC-1295 (No DAC) Blend<\/td><\/tr>\n
Identity<\/th>Two-component blend: Ipamorelin (pentapeptide, GHRP class) + CJC-1295 No DAC \/ Mod GRF 1-29 (29-amino acid peptide, GHRH analogue class)<\/td><\/tr>\n
Synonyms<\/th>Ipamorelin, CJC-1295, Mod GRF 1-29, GHRP, GHRH<\/td><\/tr>\n
Research context<\/th>GHS-R binding models (Ipamorelin), GHRH receptor binding models (CJC-1295 No DAC), in vitro<\/td><\/tr>\n
CAS number<\/th>Ipamorelin: 170851-70-4 \u00b7 CJC-1295 (No DAC): 863288-34-0 (the batch-specific COA is authoritative)<\/span><\/td><\/tr>\n
Molecular formula<\/th>See CoA<\/td><\/tr>\n
Form<\/th>Lyophilised powder (freeze-dried), sealed vial<\/td><\/tr>\n
Amount<\/th>5 mg Ipamorelin + 5 mg CJC-1295 (No DAC) per vial<\/td><\/tr>\n
Purity<\/th>\u226599% (HPLC), identity confirmed by LC-MS<\/td><\/tr>\n
Analysis<\/th>External third-party laboratory, batch-specific COA<\/td><\/tr>\n
Intended use<\/th>For Research Use Only (RUO)<\/td><\/tr>\n
Price<\/th> \u00b7 Shipping from Germany<\/td><\/tr>\n <\/table>\n\n

What is Ipamorelin + CJC-1295 (No DAC)?<\/h2>\n

This product is a Two-component blend<\/strong> from two different peptides that are assigned to separate substance classes. Ipamorelin<\/strong> is a pentapeptide and belongs to the class of growth hormone-releasing peptides (GHRPs). CJC-1295 (No DAC)<\/strong> \u2013 also referred to as Mod GRF 1-29 \u2013 is a 29-amino acid peptide from the GHRH analogue class. Both components are supplied as a stable lyophilised product in a sealed vial (5 mg per component). They serve as well-characterised reference substances in laboratory research. The respective CAS numbers are provided above; the molecular formulas are documented in the batch-specific certificate of analysis.<\/p>\n\n

Molecular profile & target structure<\/h2>\n

The two peptides differ structurally and in their class affiliation. Ipamorelin<\/strong> is a short pentapeptide and is attributed in the literature to the GHRP class, whose substances in binding models at growth hormone secretagogue receptor (GHS-R)<\/strong> to be investigated. CJC-1295 (No DAC)<\/strong> is a longer 29-amino acid peptide and is derived from the N-terminal fragment of growth hormone-releasing hormone (Mod GRF 1-29); it belongs to the class of GHRH analogues<\/strong> assigned and characterised in binding models at the GHRH receptor. The combination of defined sequences, clear class assignment, and good analytical characterisability makes the blend a frequently referenced substance combination in the preclinical literature for receptor biochemical study models.<\/p>\n\n

What in-vitro and animal model studies document<\/h2>\n

The following summary reflects only what is described in the publicly accessible preclinical literature<\/strong> \u2013 it is not a statement about an effect or suitability in humans.<\/p>\n